Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
Pfizer has signed a strategic funding agreement with Blackstone Life Sciences to advance its monthly GLP-1 obesity drug berobenatide through Phase 3 studies. Blackstone will provide up to $1.5 billion through 2028, according to PharmaExec. Pfizer acquired the asset by winning a bidding war for Metsera, the drug's previous owner. The deal supports a sprawling Phase 3 program as Pfizer seeks to compete in the crowded weight-loss drug market.
Listen to Live Briefing
Real-time synthesized voice briefing Β· Live Feeds Desk
- β Pfizer and Blackstone Life Sciences signed a co-funding deal in which Blackstone will provide up to $1.5 billion through 2028 to advance berobenatide.
- β The funding supports a Phase 3 program for a monthly GLP-1 obesity shot Pfizer acquired by winning a bidding war for Metsera.
What changed
Pfizer and Blackstone have announced a co-funding agreement for berobenatide, replacing earlier speculation that Pfizer would fund the obesity program entirely from its own balance sheet.
Live updates
-
Pfizer and Blackstone agree up to $1.5 billion co-funding deal for obesity drug berobenatide
Pfizer has signed a strategic funding agreement with Blackstone Life Sciences to advance its monthly GLP-1 obesity drug berobenatide through Phase 3 studies. Blackstone will provide up to $1.5 billion through 2028, according to PharmaExec. Pfizer acquired the asset by winning a bidding war for Metsera, the drug's previous owner. The deal supports a sprawling Phase 3 program as Pfizer seeks to compete in the crowded weight-loss drug market.
Why it matters
The agreement shifts much of the financial risk of late-stage obesity drug development onto Blackstone while Pfizer retains a path to commercialization. Berobenatide is a once-monthly GLP-1 shot positioned as Pfizer's answer to Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The Metsera acquisition gave Pfizer control of the candidate after a competitive auction. What remains unresolved is how the economics are split between the two parties and when Phase 3 data will read out.
What is confirmed
- Pfizer and Blackstone Life Sciences signed a co-funding deal in which Blackstone will provide up to $1.5 billion through 2028 to advance berobenatide.
- The funding supports a Phase 3 program for a monthly GLP-1 obesity shot Pfizer acquired by winning a bidding war for Metsera.
Still unconfirmed
- Pfizer will retain full commercialization rights to berobenatide after Blackstone's funding commitment ends.
- Blackstone's investment will secure Pfizer a top-three position in the global obesity drug market by 2029.
What to watch next
- Phase 3 trial initiation and enrollment targets for berobenatide
- Disclosure of revenue-sharing and milestone terms between Pfizer and Blackstone
- Top-line readout timing for the monthly GLP-1 obesity shot
confidence 90%Sources used for this update (17)
- www.marketscreener.com β Global Stocks Fall on Higher Oil Prices, AI Pullback | MarketScreener
- www.biospace.com β GSK restructure will hit home, impacting 'limited' UK roles
- www.wallstreetzen.com β Sandisk Stock Price Today (NASDAQ: SNDK) Quote, Market Cap, Chart
- WSJ β Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
- Reuters β Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
- Yahoo Finance β Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
- Bloomberg.com β Blackstone Puts Up $1.5 Billion for Pfizer Obesity Drug Studies
- Stocks Down Under β Pfizer (NYSE:PFE) Is Getting $1.5bn From Blackstone To Fund Its GLP-1 Ambitions
- Fierce Biotech β Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
- Quartz β Pfizer is tapping Blackstone for up to $1.5 billion to fund its weight-loss drug
- Barron's β Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
- BioPharma Dive β Blackstone bets $1.5B on Pfizerβs obesity drug
Community Sentiment: How do you assess this situation?
Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community